Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
Top Cited Papers
Open Access
- 1 April 2012
- journal article
- review article
- Published by Wiley in European Journal of Heart Failure
- Vol. 14 (4), 341-343
- https://doi.org/10.1093/eurjhf/hfs033
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Journal of the Renin-Angiotensin-Aldosterone System, 2012
- Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) studyEuropean Journal of Heart Failure, 2011
- Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)European Journal of Heart Failure, 2011
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart FailureCirculation, 2009
- Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trialEuropean Journal of Heart Failure, 2009
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designNephrology Dialysis Transplantation, 2009
- Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart FailureCirculation: Heart Failure, 2008
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialThe Lancet, 2003